ECONOMIC BENEFITS OF SFLT-1/PLGF TESTING FOR PREECLAMPSIA IN COLOMBIA- A FIVER YEAR BUDGET IMPACT ANALYSIS
Author(s)
Duva AS1, Rosim RP1, Ballalai Ferraz AF1, Cachoeira C2, Mojica IL3
1QuintilesIMS, São Paulo, Brazil, 2Roche Brazil, São Paulo, Brazil, 3Roche Colombia, Bogota, Colombia
OBJECTIVES:: To assess the five-year budget impact of SflT-1/PlGF testing women with suspected preeclampsia in the Colombian public healthcare setting. METHODS:: Demographic data from the Colombian statistics bureau and the World Bank was used in combination with the installed equipment base necessary for testing and with health insurance coverage data in order to calculate the number of women with suspected preeclampsia who are within geographic reach of testing and are covered by the Colombian public healthcare system. This data was then fed into a budget impact model based on three stages of women with suspected preeclampsia management: low-intensity, intermediate-intensity and high-intensity. Both base case (taking into account standard diagnosis methods) and SflT-1/PlGF testing scenarios were modelled with the same management assumptions, diverging only in the proportion of women per management scheme. Costs were extracted from a Colombian public healthcare system reference list and were attributed to exams, in-patient care, antihypertensive therapy and medical appointments. RESULTS:: It is expected that from 2017 to 2021 up to 215,696 women will present a suspicion of preeclampsia in the Colombian public healthcare system. In the base case scenario a total cost of COL 332 billion was associated with the management of these patients, in contrast to a total cost of COL 284 billion in the SlfT-1/PlGF testing scenario, resulting in a five-year resource economy of COL 47 billion, or COL 182,841 per patient. This economy is driven by a reduction in the amount of hospitalizations: in base case scenario, 36% of all women were hospitalized against 16% in the SflT-1/PlGF scenario, a 59% reduction. CONCLUSIONS:: Even though SflT-1/PlGF testing increases the costs associated with diagnosing preeclampsia, incremental costs are offset by a reduction in the number of unnecessary hospitalizations, generating economy to the Colombian public health system.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD6
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Reproductive and Sexual Health